CF-404 is a therapeutic cocktail composed of three fully human monoclonal antibodies designed to treat all seasonal and most pandemic strains of human influenza. The goal of the CF-404 program is to create a universal influenza therapy covering all human seasonal strains by targeting highly conserved sites on a diverse family of influenza viruses. Animal studies show that CF-404 protects animals from a broad range of influenza viruses. These highly potent antibodies are effective at low doses and have the potential to be active when administered beyond the treatment window limit for current influenza therapies, which are indicated to be used within 48 hours of symptom onset.
- Inhaled therapy treats infection directly in the respiratory system
- Provides coverage of all human seasonal influenza strains in a single treatment
- Extends the treatment window beyond 48-hours after the onset of symptoms
Every year a significant number of people develop a serious influenza infection despite the availability of seasonal flu vaccine. According to the CDC, on average over 200,000 people are hospitalized and up to 49,000 people die each year in the U.S. from seasonal flu-related illness. This is particularly problematic in individuals with less robust immune systems such as infants, elderly individuals, and patients who are otherwise immunocompromised such as those with HIV/AIDS, receiving cancer chemotherapy, or using transplant rejection therapies. ContraFect's antibody cocktail is designed to treat patients who become seriously ill with influenza.
Annual hospitilizations due to influenza, in the U.S.
Annual deaths due to influenza, in the U.S.
Exebacase is an investigational novel lysin being studied in clinical trials as a treatment for patients with Staph aureus bacteremia, including endocarditis, caused by MRSA or MSSA.View CF-301 »